NASDAQ · Diagnostics & Research · USD

Advanced Biomed Inc. (ADVB) Stock Analysis

Advanced Biomed Inc. (ADVB) is a Diagnostics & Research stock listed on NASDAQ and quoted in US Dollar.

ADVB

$9.34

−$0.06 (−0.69%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ADVB with… →

ADVB Key Statistics

As of Sep 4, 2026

Trading

Open: $9.33
Previous Close: $9.40
Day's Range: 9.10–9.44
52-Week Range: 3.61–24.23
Volume: 66.50K

Valuation

Market Cap: $15.42M
P/E Ratio: 2.35
EPS (ttm): 3.97

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$2.78M
Profit margin: 0.00%
Shares Outstanding: 1.65M
1-Year Return: +8.55%

Dividend and dates

Avg Volume: 1.80M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ADVB Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

Year	Return
2026 (partial year)	+59.85%
2025 (partial year)	−92.00%

As of September 4, 2026.

ADVB Revenue and Earnings by Fiscal Year

FY ends June

RevenueNet income

202220232024

Fiscal year	Revenue	Net income	Net margin
2024	$0.00	−$2.78M	—
2023	$0.00	−$3.73M	—
2022	$0.00	−$4.03M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2024	$0.00	—	−$2.54M	−$2.78M	—
2023	$0.00	—	−$3.07M	−$3.73M	—
2022	$0.00	—	−$2.37M	−$4.03M	—

Annual figures as reported, in the company's reporting currency. As of June 30, 2024.

ADVB Valuation vs Diagnostics & Research Median

Median of 49 stocks

Metric	ADVB	Diagnostics & Research median	vs median
P/E	2.35	33.08	0.1x the median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 49 Diagnostics & Research stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Advanced Biomed Inc. (ADVB) is capitalised at $15.42M on the latest close. The company sits in the Healthcare sector, in the Diagnostics & Research industry. Headcount on file is 31.

Over the past 52 weeks the price has ranged from $3.61 to $24.23. The most recent close on file for ADVB is $9.34, dated September 4, 2026. That is −$0.06 (−0.69%) against the previous close. The latest close sits 158.59% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2024, shows revenue of $0.00. The same year closed with a net loss of $2.78M. Profit margin runs at 0%. Earnings per share on a trailing basis come to 3.97.

Across the 3 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2024. Of those 3 years, 0 report positive net income.

Valuation Assessment

ADVB trades at a trailing price-to-earnings ratio of 2.35. That is 0.1 times the Diagnostics & Research median of 33.08. The medians here are taken across 49 Diagnostics & Research companies that report the metric.

Over the trailing twelve months the price has returned +8.55%. Daily returns over the trailing 1 year annualize to a volatility of 169.6%.

Growth & Income

No dividend is on file for ADVB.

2026 is still running; the price is +59.85% year to date.

Peer Comparison

Advanced Biomed Inc. (ADVB) operates in the Diagnostics & Research industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Advanced Biomed Inc.	ADVB	$15.42M	2.4
Thermo Fisher Scientific Inc.	TMO	$226.94B	33.0
Danaher Corporation	DHR	$145.98B	37.0
Natera, Inc.	NTRA	$47.31B	—

The Diagnostics & Research industry average P/E ratio is 33.1x. Advanced Biomed Inc. trades at a P/E of 2.4.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Diagnostics & Research Stocks

TMO

Thermo Fisher Scientific Inc.

$226.94B

DHR

Danaher Corporation

$145.98B

NTRA

Natera, Inc.

$47.31B

IQV

IQVIA Holdings Inc.

$44.07B

Agilent Technologies, Inc.

$42.54B

IDXX

IDEXX Laboratories, Inc.

$42.18B

View all Diagnostics & Research stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Advanced Biomed Inc.

Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies for precision oncology detection, diagnosis, and treatment in Taiwan. Its devices include A+Pre, an automated sample preparation system that enables pre-concentration of diluted blood samples; AC-1000, a rare cell device to solve the problem of detection of hypercoagulable state samples of tumor patients; A+SCDrop, a circulating tumor cell (CTC) single-cell capture device; and A+CellScan, an analyzer with an immunostaining chip for immunostaining/analysis of the AC-1000 product. The company also offers microfluidic biochips, such as A+Pre, AC-1000 CTC enrichment, and A+CellScan chips to provide assay products and services to cancer patients. In addition, its immunochromogenic kits include A+CTCE kit to identify epithelial circulating tumor cells and determined by the immunochromogenicity of EpCAM, CK (pan), CD45, and CD14 antibodies; A+CTCM kit to identify mesenchymal circulating tumor cells based on the immunochromogenicity of Vimentin, CD45, and CD14 antibodies; A+EMT to identify epithelial-to-mesenchymal circulating tumor cells determined by the immunochromogenicity of cell-surface Vimentin, and CD45 and CD14 antibodies; and A+CM to identify tumor-associated macrophages based on the immunochromogenicity of PD-L1, CD45, and CD14 antibodies. Further, the company is developing A+LCGuard for early screening of lung cancer. Additionally, it establishes and operates medical clinics in the People's Republic of China. The company was founded in 2014 and is headquartered in New York, New York.

Visit website →